Journal
RADIATION RESEARCH
Volume 175, Issue 2, Pages 214-224Publisher
RADIATION RESEARCH SOC
DOI: 10.1667/RR2323.1
Keywords
-
Funding
- Department of Radiation Oncology, Washington University School of Medicine
- Dr. Joseph Roti Roti and Stephanie Pagano Fund for Mesothelioma Research
- American Cancer Society [IRG-58-010-51]
- Wendy Will Case Cancer Fund
Ask authors/readers for more resources
mTOR (mammalian target of rapamycin) signaling plays a key role in the development of many tumor types. Therefore, mTOR is an attractive target for cancer therapeutics. Although mTOR inhibitors are thought to have radiosensitization activity, the molecular bases remain largely unknown. Here we show that treating MCF7 breast cancer cells with rapamycin (an mTOR inhibitor) results in significant suppression of homologous recombination (HR) and nonhomologous end joining (NHEJ), two major mechanisms required for repairing ionizing radiation-induced DNA DSBs. We observed that rapamycin impaired recruitment of BRCA1 and Rad51 to DNA repair foci, both essential for HR. Moreover, consistent with the suppressive role of rapamycin on both HR and NHEJ, persistent radiation-induced DSBs were detected in cells pretreated with rapamycin. Furthermore, the frequency of chromosome and chromatid breaks was increased in cells treated with rapamycin before and after irradiation. Thus our results show that radiosensitization by mTOR inhibitors occurs via disruption of the major two DNA DSB repair pathways. (C) 2011 by Radiation Research Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available